Form 4: Akero Therapeutics Chief Scientific Officer Donates 14,000 Shares
SEC Form 4 Filing
Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, donated 14,000 shares of common stock to a donor advised fund.
Summary
- Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, donated 14,000 shares of the company's common stock to a donor advised fund.
- The transaction occurred on January 7, 2025.
- Following the transaction, Mr. Rolph directly owns 170,237 shares of Akero Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a neutral report of a stock donation, with no positive or negative implications for the company's performance.
Industry Context
This is a routine filing related to insider transactions and does not indicate any specific trend in the biotechnology industry.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, and this transaction is consistent with typical insider activity.
- Similar filings are common across the biotechnology sector when executives make stock transactions.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a donation and not a sale of shares on the open market.
Key Dates
| Date | Description |
|---|---|
| 01/07/2025 | Date of the stock donation transaction. |
| 01/10/2025 | Date the form was signed. |
Keywords
Akero Therapeutics, Timothy Rolph, stock donation, insider transaction, common stock, donor advised fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.